PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Pathfinder finds way forward in Mozambique

Wed, 22nd Mar 2023 10:30

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Pathfinder Minerals PLC, up 21% at 0.55 pence, 12-month range 0.35p - 0.95p. The Mozambique-focused natural resources firm enters into a conditional agreement with Acumen Advisory Group LLC for the sale of IM Mineral Ltd, its wholly-owned subsidiary. With it, Pathfinder disposes of the rights to bring a claim against the government of Mozambique for the expropriation of mining concession 4623C. Completion of the disposal is conditional upon shareholder approval at Pathfinder's general meeting on April 26. Completion will result in a payment of GBP2 million from AAG to Pathfinder, a commitment by AGG to begin legal proceedings against the government of Mozambique, and a contingent payment of USD24 million, or 20% of the net recoveries from any settlement or determination of the claim against the Mozambique government.

----------

Evgen Pharma PLC, up 4.9% at 4.04 pence, 12-month range 2.83p - 7.80p. The clinical-stage drug development company announces top line pharmacokinetic data for its placebo-controlled, dose-escalating, randomised Phase I/Ib clinical trial. The study aimed to provide further insight into the pharmacokinetic and pharmacodynamic characteristics of the new enteric coated tablet formulation of the company's lead asset SFX-01, as well as investigating how sulforaphane released from the tablet engages with targets of interest. Says sulforaphane was released by the enteric coated tablet beyond the acid environment of the stomach as predicted, and the levels of sulforaphane and its active metabolites in blood increased predictably with increasing doses. Notes that the total levels of sulforaphane and active metabolites in blood were in the range previously seen to be effective in pre-clinical experiments and clinical studies in a range of target diseases including breast cancer and glioblastoma.

----------

AIM - LOSERS

----------

Anpario PLC, down 27% at 225.00 pence, 12-month range 225.00p - 611.50p. The animal feed additive manufacturer reports a drop in annual profit due to declining demand and higher costs. Pretax profit falls 35% to GBP3.7 million in 2022 from GBP5.7 million the year prior, as its gross margin worsens to 43% from 49%. Revenue edges down to GBP33.1 million from GBP33.4 million. Says the year suffered from supply chain disruption and "significant and immediate" raw material and logistics price inflation. Explains this also hurt many of the farmers that are customers of Anpario. Farmers experienced input cost pressures, notably feed and energy, cutting their profitability and in some cases viability, according to Anpario. "Some farmers, particularly across the UK and Europe, decided to forgo unprofitable production which is now leading to specific food shortages in the retail channels. With less animals being reared the demand for animal feed and therefore additives is inevitably lower and partly explains the group's disappointing performance across Europe," it says. Nonetheless, firm proposes an increased final dividend of 7.35 pence, up from 7.0p the year prior.

----------

Mpac Group PLC, down 13% at 243.55 pence, 12-month range 210.00p - 534.00p. The automation ecosystem maker says pretax profit plunges to GBP200,000 in 2022 from GBP8.2 million in 2021, as cost of sales rises to GBP73.3 million from GBP65.4 million, and distribution expenses widen to GBP8.1 million from GBP6.8 million. Revenue, meanwhile, rises to GBP97.7 million from GBP94.3 million. Chief Executive Tony Steels explains that the year was characterised by "increased macro-economic uncertainty and unprecedented volatility in the global supply chain" which lengthened the lead time of customers' order placement and caused operational challenges. This resulted in lower order intake, reduced operational efficiency, and extended project build time-frames. Mpac adds that rising energy costs, higher interest rates, skilled labour shortages, and semi-conductor supply constraints are expected to continue into 2023, which it says "sets the context" for customer investments and decision-making. Separately, the firm announces that Adam Holland, its chief operating officer, will succeed Tony Steels as chief executive. Steels retires from the company after being CEO for more than six years. Says there will be a handover period, with Steels formally stepping down on May 17.

----------

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
7 Aug 2019 11:47

Evgen Pharma Gets European Patent Covering Composition Of SFX-01

(Alliance News) - Evgen Pharma PLC on Wednesday said it has secured further intellectual property rights in Europe for SFX-01.The drug development company, focused on breast cancer and said

Read more
5 Aug 2019 11:45

Evgen Pharma To Collaborate With King's College And British Heart

(Alliance News) - Evgen Pharma PLC said Monday that it backs the new research collaboration between King's College London and the British Heart Foundation.The collaboration is how - - a

Read more
18 Jul 2019 13:00

Evgen Pharma Outlook Confident As Progresses Programmes Development

(Alliance News) - Evgen Pharma PLC on Thursday expressed confidence for the year ahead as it continued to progress on the development of its clinical programmes.Ahead of its annual general

Read more
13 Jun 2019 12:21

Evgen Pharma Annual Loss Fractionally Wider On Small Expense Rise

(Alliance News) - Evgen Pharma PLC on Thursday said its loss marginally widened in its most recent financial year due to slightly higher expenses as drug development continues.Clinical drug

Read more
13 Jun 2019 09:03

Evgen Pharma losses edge wider on higher costs

(Sharecast News) - Evgen Pharma on Thursday reported a slightly widened annual loss due to a cost increase, with its results in line with expectations as its drugs remain in the development stage.

Read more
17 Apr 2019 13:17

Evgen Pharma Raises GBP5 Million Via Share Placing (ALLISS)

LONDON (Alliance News) - Evgen Pharma PLC said Wednesday it raised GBP5.0 million via issue of shares in an oversubscribed placing.The clinical stage drug development company issued 13.1 at

Read more
25 Mar 2019 10:23

Good Headline Results From Evgen Pharma Breast Cancer Study Of SFX-01

LONDON (Alliance News) - Evgen Pharma PLC on Monday announced positive headline results from its phase two Stem trial of SFX-01 in advanced breast cancer.Shares in the clinical-stage drug -

Read more
18 Mar 2019 11:10

Evgen Pharma Expects STEM Trial Read-Out Next Week

LONDON (Alliance News) - Evgen Pharma PLC on Monday said it expects the final read-out of its STEM trial in metastatic breast cancer to be announced early next week, in line with its guidance of

Read more
5 Mar 2019 11:35

Study Of Evgen Pharma's SFX-01 Multiple Sclerosis Drug Shows Promise

LONDON (Alliance News) - Clinical stage drug developer Evgen Pharma PLC on Tuesday said a study has been published showing that its lead product, SFX-01, reduces residual disability in a model of

Read more
5 Feb 2019 09:18

Evgen Pharma Finishes Patient Recruitment For Stroke Treatment Trial

LONDON (Alliance News) - Evgen Pharma PLC on Tuesday said it has completed patient recruitment in its SAS phase II trial for proposed treatment SFX-01.SFX-01 is a planned treatment for a an

Read more
12 Dec 2018 11:11

Evgen Pharma Interim Loss Widens As It Progresses New Drug Trials

LONDON (Alliance News) - Evgen Pharma PLC on Wednesday said its interim loss widened slightly for its most recent half as it focuses on advancing trials.For the six month to September 30, a

Read more
12 Dec 2018 10:10

Evgen Pharma's loss widens amid excitement over cancer treatment

(Sharecast News) - Evgen Pharma's shares stumbled on Wednesday after its interim loss before tax expanded, though the company was "delighted" by progress in treatment developments.

Read more
23 Oct 2018 12:55

David And Monique Newlands Build 5% Stake In Evgen Pharma (ALLISS)

LONDON (Alliance News) - Evgen Pharma PLC said Tuesday that David and Monique Newlands now own 5.06% stake in the company.The Newlands' holding before the transaction, if any, was not

Read more
18 Oct 2018 10:26

Evgen Pharma Raises GBP750,000 Via Share Placing (ALLISS)

LONDON (Alliance News) - Evgen Pharma PLC said Thursday it raised GBP750,000 via share placing.The company issued 5.6 million shares at 13.5p. Shares in the drug development company were at

Read more
11 Sep 2018 12:51

Tueday broker round-up

(Sharecast News) - JD Wetherspoons: Berenberg upgrades to buy with a target price of 1,450p.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.